FindTrial
Sign In

Establishment and application of an B cell epitope vaccine in the treatment of Otorhinolaryngological diseases with allergic inflammation

Construction and application of dust mite allergen specific B cell epitope vaccine

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-BOR-17011881
Enrollment
Unknown
Registered
2017-07-05
Start date
2017-07-07
Completion date
Unknown
Last updated
2017-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

Allergic rhinitis:Venous blood sampling
Healthy control:Venous blood sampling

Sponsors

Shenzhen science and technology innovation commission
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients with mild or moderate allergic rhinitis were clinically diagnosed; 2. Previously untreated by SIT within 6 months; 3. untreated with glucocorticosteroid with in 2 weeks; 4. aged 5-60 years, female or male; 5. Serum IgE >100 IU, dust mite allergen specific IgE >0.35IU; 6. The patient volunteered to participate in this study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe allergic rhinitis; 2. Pregnant and lactating women; 3. vaccinated within 3 months; 4. Patients are being treated for desensitization; 5. other type of non-allergic rhinitis.

Design outcomes

Primary

MeasureTime frame
IgE;T cell proliferation;—

Countries

China

Contacts

Public ContactZHIQIANG LIU

Shenzhen Institute of ENT

liuzhiqiang05312438@126.com+86 15986613913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026